AnaptysBio Inc (ANAB)
20.81
-0.71
(-3.30%)
USD |
NASDAQ |
Nov 13, 16:00
20.81
0.00 (0.00%)
After-Hours: 20:00
AnaptysBio Revenue (Annual): 17.16M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.16M |
| December 31, 2022 | 10.29M |
| December 31, 2021 | 63.18M |
| December 31, 2020 | 75.00M |
| December 31, 2019 | 8.00M |
| December 31, 2018 | 5.00M |
| Date | Value |
|---|---|
| December 31, 2017 | 10.00M |
| December 31, 2016 | 16.68M |
| December 31, 2015 | 17.57M |
| December 31, 2014 | 15.84M |
| December 31, 2013 | 5.483M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
8.00M
Minimum
2019
75.00M
Maximum
2020
34.72M
Average
17.16M
Median
2023
Revenue (Annual) Benchmarks
| Eli Lilly and Co | 34.12B |
| Regeneron Pharmaceuticals Inc | 13.12B |
| Ligand Pharmaceuticals Inc | 131.31M |
| Agios Pharmaceuticals Inc | 26.82M |
| ADMA Biologics Inc | 258.22M |